Verastem, Inc. (VSTM): Price and Financial Metrics


Verastem, Inc. (VSTM): $1.25

0.02 (+1.63%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VSTM to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

VSTM POWR Grades


  • VSTM scores best on the Growth dimension, with a Growth rank ahead of 84.1% of US stocks.
  • The strongest trend for VSTM is in Growth, which has been heading up over the past 179 days.
  • VSTM's current lowest rank is in the Momentum metric (where it is better than 4.64% of US stocks).

VSTM Stock Summary

  • With a price/sales ratio of 137.05, Verastem Inc has a higher such ratio than 98.08% of stocks in our set.
  • With a year-over-year growth in debt of -85.89%, Verastem Inc's debt growth rate surpasses only 2.58% of about US stocks.
  • Revenue growth over the past 12 months for Verastem Inc comes in at -97.68%, a number that bests only 0.85% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Verastem Inc are TARS, EYEN, MNOV, YMAB, and CYTK.
  • Visit VSTM's SEC page to see the company's official filings. To visit the company's web site, go to www.verastem.com.

VSTM Valuation Summary

  • In comparison to the median Healthcare stock, VSTM's EV/EBIT ratio is 149.15% lower, now standing at -14.4.
  • Over the past 117 months, VSTM's price/sales ratio has gone NA NA.
  • VSTM's price/sales ratio has moved NA NA over the prior 117 months.

Below are key valuation metrics over time for VSTM.

Stock Date P/S P/B P/E EV/EBIT
VSTM 2021-08-31 5.9 5.4 -12.4 -14.4
VSTM 2021-08-30 6.0 5.5 -12.5 -14.5
VSTM 2021-08-27 6.2 5.7 -12.9 -15.0
VSTM 2021-08-26 5.8 5.3 -12.2 -14.1
VSTM 2021-08-25 6.1 5.5 -12.6 -14.6
VSTM 2021-08-24 5.9 5.4 -12.3 -14.3

VSTM Growth Metrics

    The year over year revenue growth rate now stands at 305.31%.
  • The 2 year net cashflow from operations growth rate now stands at -93.51%.
  • Its 2 year net income to common stockholders growth rate is now at -96.58%.
VSTM's revenue has moved down $24,704,000 over the prior 33 months.

The table below shows VSTM's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 2.014 -65.272 -74.583
2021-06-30 80.659 -9.698 -38.659
2021-03-31 84.466 -18.821 -44.767
2020-12-31 88.516 -33.506 -67.726
2020-09-30 91.626 -49.024 -86.636
2020-06-30 22.011 -121.619 -129.913

VSTM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VSTM has a Quality Grade of C, ranking ahead of 63.22% of graded US stocks.
  • VSTM's asset turnover comes in at 0.015 -- ranking 380th of 682 Pharmaceutical Products stocks.
  • NERV, BLUE, and OTLC are the stocks whose asset turnover ratios are most correlated with VSTM.

The table below shows VSTM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.015 0.994 -0.646
2021-06-30 0.510 0.602 -0.382
2021-03-31 0.478 0.611 -0.535
2020-12-31 0.455 0.619 -0.911
2020-09-30 0.476 0.624 -1.030
2020-06-30 0.118 0.856 -1.060

VSTM Price Target

For more insight on analysts targets of VSTM, see our VSTM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.25 Average Broker Recommendation 1.38 (Strong Buy)

VSTM Stock Price Chart Interactive Chart >

Price chart for VSTM

VSTM Price/Volume Stats

Current price $1.25 52-week high $4.94
Prev. close $1.23 52-week low $1.00
Day low $1.19 Volume 1,946,300
Day high $1.35 Avg. volume 2,103,956
50-day MA $1.39 Dividend yield N/A
200-day MA $2.08 Market Cap 232.95M

Verastem, Inc. (VSTM) Company Bio


Verastem, Inc. focuses on discovering and developing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. The company was founded in 2010 and is based in Needham, Massachusetts.


VSTM Latest News Stream


Event/Time News Detail
Loading, please wait...

VSTM Latest Social Stream


Loading social stream, please wait...

View Full VSTM Social Stream

Latest VSTM News From Around the Web

Below are the latest news stories about Verastem Inc that investors may wish to consider to help them evaluate VSTM as an investment opportunity.

Verastem (NASDAQ:VSTM) investors are sitting on a loss of 62% if they invested three years ago

If you love investing in stocks you're bound to buy some losers. But the long term shareholders of Verastem, Inc...

Yahoo | February 22, 2022

Kalos Management, Inc. Buys Vale SA, Sells Consensus Cloud Solutions Inc, Intuitive Surgical ...

Investment company Kalos Management, Inc. (Current Portfolio) buys Vale SA, sells Consensus Cloud Solutions Inc, Intuitive Surgical Inc, Amarin Corp PLC, Catalyst Biosciences Inc, Paratek Pharmaceuticals Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Kalos Management, Inc..

Yahoo | February 3, 2022

Verastem Oncology outlines key milestones for 2022

Verastem Oncology (VSTM) announces key strategic priorities and upcoming catalysts to support its lead compound VS-6766 in 2022.The company expects to reports results from RAMP 201

Seeking Alpha | January 11, 2022

Verastem Oncology Outlines Key 2022 Strategic Priorities and Upcoming Catalysts for Advancing VS-6766 as a Backbone of Therapy for RAS Pathway-Driven Cancers

BOSTON, January 11, 2022--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today outlined key strategic priorities and upcoming catalysts to support its lead compound VS-6766 in 2022. VS-6766 is a RAF/MEK clamp that induces inactive complexes of MEK with ARAF, BRAF and CRAF, potentially creating a more complete and durable anti-tumor response through maximal RAS pathway inhibition. VS-6766 is currently in late-stage d

Yahoo | January 11, 2022

Verastem Oncology grants under nasdaq listing rule 5635(c)(4)

Verastem Oncology (VSTM) grants inducement options to purchase 1,625 shares of its common stock and the grant of 813 restricted stock units (RSUs) to two new employees.The options have

Seeking Alpha | January 7, 2022

Read More 'VSTM' Stories Here

VSTM Price Returns

1-mo -17.22%
3-mo 0.00%
6-mo -56.29%
1-year -60.82%
3-year -16.11%
5-year -49.60%
YTD -39.02%
2021 -3.76%
2020 58.96%
2019 -60.12%
2018 9.45%
2017 174.11%

Continue Researching VSTM

Here are a few links from around the web to help you further your research on Verastem Inc's stock as an investment opportunity:

Verastem Inc (VSTM) Stock Price | Nasdaq
Verastem Inc (VSTM) Stock Quote, History and News - Yahoo Finance
Verastem Inc (VSTM) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7768 seconds.